{"name":"Nuvalent Inc.","slug":"nuvalent-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Neladalkib (NVL-655)","genericName":"Neladalkib (NVL-655)","slug":"neladalkib-nvl-655","indication":"ALK-positive non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Neladalkib (NVL-655)","genericName":"Neladalkib (NVL-655)","slug":"neladalkib-nvl-655","phase":"phase_3","mechanism":"Neladalkib is a selective ALK (anaplastic lymphoma kinase) inhibitor that blocks ALK-driven signaling in cancer cells.","indications":["ALK-positive non-small cell lung cancer","ALK-positive solid tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQTGlad1E1MVJNUGlycHczYnJfdHFBblpaN0VwUlZZdUlrS3R0U2NRelZUZFdwak5LTFZ0Szh2UEsya3REZDZhUWI4V1NLNk05MFI5OVR1YjlVQkJHdGNoZG9sSFl3M2NGcWE3YjhTWktJTUlndW16azctbmpsQjZNYjc3Yk5WV2JBS050cVo3STFFZDU1NGljbTBadFZtQWJoMDBOS2g5TExmelRaZE5MazEwQVlBaGw0T0dQNjN3aXFLUVdrN1U2UThSbHRMOFFoS2hPVkY2NWxGdWdPZ2Z4eXFkaUMydXh6NFF5cGtkY0Q0QXVwNjdNWjFRUU4?oc=5","date":"2026-03-15","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQaGZaendLNlBmQmtqTm1ELTdrVktjTFJLdEE2NXFFZEJWR3h2QV9sZmRNbER2MVVJeDQ0X2lCSXVIcm0tejBxeTNvMkpWanJnaXNmVmRLeEdOUmJiR1p3c21UUDlZTHdHRjE2cVg4OElQNTB2WC1KX25fTFdjZ3U3anliV0tRZ0RfTUhnaV96ai00NlQ3OXBVRjlzWXVmWVY1MTg0eQ?oc=5","date":"2025-12-29","type":"pipeline","source":"NAI500","summary":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","headline":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOV245XzItS094TDhWNV9hWGhKU3NmaDBHZ25idGFZck9wUjQ4UVBBbUNiTVBNOUROa25QZGdDbllTMmE0VmhoQXdqRE1GVWdYZW9Bei1oVnNEaUExVXJJOHZkV05xLXAwc204RXdEakREY2JZc2V3UzJMMmpxV01PM0ctNnZqQkVXQUpIaXgtQ3lzTHlIR3RGTDNfVV9NYjVfWmpMX2g2NmUtX3o3V3djU25zc1FJa1ZYMXY3VTdpLXlLY2RXb1BJ?oc=5","date":"2025-12-29","type":"pipeline","source":"The Globe and Mail","summary":"3 Biotech Stocks With Major 2026 Catalysts - The Globe and Mail","headline":"3 Biotech Stocks With Major 2026 Catalysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOR0JPTnZGNThTNFVTT0RSWjNHMXZyNDRLTjBDVC14Z1B5STlFeWpaN1lVNGxDOUduSVRjNmpkN2lpTU1QR3g5WDFfcmI3OUN0ZnVqWmVSR3ZGYkVBUF9jdFZ0REszZmZldFNvU19XRUs1dzVMNno0V3Q1X05lM0tDRjVXeXM2Vmdua3ZBbkdvbThnekJmR25WQWl1TkJsdHl2cE1UN3JZdnNMQ1FaUXdoVVBkMVFrOW4xV0hUZUx4YnE0LWlHQjY4NWtB?oc=5","date":"2025-12-17","type":"deal","source":"Investing.com","summary":"UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com","headline":"UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNbXdnYVhLaUNjQnRhejJyOWlwTVU2ODNFeEZaX09OYzVORHBXMm1IaXRmdVd0WXp4YXA0QV8tTmxpVW1xVFhXNEp3WS11cGE3TFZrRnZkaXVsblBaYTRMOGFxa0JOX2UzWFpOZHpqazBJZFN0LTVFaGg4ajdHWDJ4YkhWMldTUzVqSnVsaEVQSnlPVXJZZWQ2WlUxb2NzTzI5OEpBeDMyUE5qMnlybmdoU3JnNFRhUG82SGg5WU1ac2RSaUJjNXR0WGZYZGhLT00?oc=5","date":"2025-11-26","type":"pipeline","source":"PR Newswire","summary":"Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - PR Newswire","headline":"Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOQVp5QVlla0ctVkpPaE1DWEVxQm94QWtOU2g0YzFkVUVaNzJrcUhHSks1U1RCeHRXNmtNM0RXS0oxOTBMbGdTT242cGNZSHZNQS1XSmdVczdQS0tBTzJTQ0k5Y3ZrdXJiN1BhdlpjNGZ5bnpQaE5XWjVlNFdWdmJXTFpRS2VsWndwaFJ6cWkydl82UnFoYjRzZkhFeXZzUmJLckdr?oc=5","date":"2025-11-17","type":"pipeline","source":"Stocktwits","summary":"Why Did Nuvalent Stock Surge 15% Today? - Stocktwits","headline":"Why Did Nuvalent Stock Surge 15% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOaE02cjVia1hoa0RGX1otZ1lRajd4R1E3ZzQ5NHRlOHVfbDV3VkpCdUxpREpfSmkwMkNmU1U3aWI3M1RYUFZOS0YtNzZaNU1lSDU2YzFMQU83Z3dyNUljTzF3V2lWd3dsSVZlOVJyRjRKYmJabnpSRHFIUmF1SzJRTC15WVJzZ2RMSkluRUVyUElwZWlBN1l2TWhCMnBIdFZlTEUwUTRZMFNfRnRQYkV2U25ZbHhQREtBQjhOOG5oaDhySU9XZUdZenhTMFFzclE?oc=5","date":"2025-11-17","type":"pipeline","source":"Benzinga","summary":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga","headline":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNMWZ0cG9acWVRN2FKWTU4YVlZZGU4OFlvdTJMLXoxSXRWT2tjeUd5bk45RzREaXBKMUpyVVJWa3g0OXZiWDdtTmJJVjRKcnZJazVKY1dtOENMM2R2TUQtZFg5eVhDazI1NjZRN3lHNkM0MkRVT1BPQkV1X0RuN29oU2xZY051Y0VvdE1kdWJyXy1IanpSQ29qWTB6YTRlQl9vbkRNdmZ1YVc1OHUwa3c?oc=5","date":"2025-09-10","type":"pipeline","source":"Pharmacy Times","summary":"Zidesamtinib Shows Clinically Meaningful Activity, Durability in ROS1+ NSCLC - Pharmacy Times","headline":"Zidesamtinib Shows Clinically Meaningful Activity, Durability in ROS1+ NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPdDVyeDU5Rk02VHZSVDd5LUw4WTM5b2J0VWdPY3hrdXhPcDRycDZzUkJYdGplSGdTb1dYNFZWWG9VNmFZR1EwSGEwTkprdm01ZUQ0ZGZrMlUzcWZ2ZzVqdHM2V2dIdVlhQzc5SVVZZDhVSTNTLTBodnVQaEJMVVowQUFuM0pHOEpCanJBZDdhRW9XYi1TZHhueTZHdTBadzA?oc=5","date":"2025-07-21","type":"trial","source":"Pharmacy Times","summary":"Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times","headline":"Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNbFIyYmJycElFOHI3SkZnSGZQZ0psejhJQkk1V1hZUlFPZDFrVWxWeVJMZWZZYzNzdVFDbEV0SDBlMEZGY04xbWRsTGh6YlVHcHNlTHhzV3p3VVl1d1VlRlJWejdOaTVGRFVEMFB3QmZ4NXZFcDVrT1JsbV9ZWjBKR0VkMA?oc=5","date":"2025-06-24","type":"pipeline","source":"pharmaphorum","summary":"Nuvalent chases after Nuvation in ROS1 lung cancer - pharmaphorum","headline":"Nuvalent chases after Nuvation in ROS1 lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPUnVGQ2ItRGRObTluanhkTzNvSi1nZlJZSDJidVFYLTRLVkRzTGlFZWlqQ1JXLVI1Z0t2WGk5eHB6Y1p4UWVueHpvOE5Cekx2Z1RiNlFNdUJQdWZYWHp4cjdqdG1UYVZtbHRLb0l5cXR3V2JIWng5cWpVTVprYzNLbVpXa1UtZHpqTloyQkphckJwZHU0clBSUHNJeHJobE8zVjk1MmU3eVc?oc=5","date":"2025-06-24","type":"regulatory","source":"BioPharma Dive","summary":"Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug - BioPharma Dive","headline":"Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOSzNaQ2czbDVwV01hX3hvOTE2WVlfY0FZT2I0VFdVZzcweDFKS0NrS3Jhb0t1X3Roa05NTXI3TGdPTVY3R0FLSlNySGZGcVdpY2R1dWNFOGpGM0l6WEhrUnlYZ3hoODM4bmlOMGhsdVpEVHRhdFRMaGlzc2NTOGpiNU41bG1lcGNlTVFoRW1CSVFucS1NdGJJSEMzZmZTamJ5M3ctdk1rdWNxM3N2R2VLOTIwdEVSZGZ5cnVZSmZEZGZVUWJDc2R1a2h1Qm9qY2NEdXhDVnFEekFMTTVFSExlOFp5d0FiSHAyRHV3YkhDMUpKZmt5RVZoSnhEVjktR0JlRUg1NnZKd3FTaDVKbThsWExRNGk5NVJpbzJKRXJ2Sm9kNnJl?oc=5","date":"2025-05-08","type":"earnings","source":"PR Newswire","summary":"Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results - PR Newswire","headline":"Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarte","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}